<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-116713</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Phosphotyrosine phosphatase SPH-1, somastostatin and prostate cancer</dc:title>
<dc:description xml:lang="en">We review the mechanisms involved in prostatic growth based on androgens and product of neuroendocrine secretion, with special reference to the role of somatostatin (SS) in the inhibition of neoplastic growth. Our contributions in the field confirm the antiproliferative effect of SS on the prostate is mediated by phosphotyrosine phosphatase SHP-1, that is present in human prostate. This enzyme plays a role in the control of prostatic cell proliferation and in the progression of prostate cancer. Besides, we consider its presence may determine the therapeutic potential of SS in the control of prostate cancer (AU)</dc:description>
<dc:creator>Colas, B</dc:creator>
<dc:creator>Ropero, R. M</dc:creator>
<dc:creator>Zapata, P. D</dc:creator>
<dc:creator>Angulo, J. C</dc:creator>
<dc:creator>López, J. I</dc:creator>
<dc:creator>Martín, R. M</dc:creator>
<dc:creator>Rodríguez, F. J</dc:creator>
<dc:creator>López-Ruiz, P</dc:creator>
<dc:creator>González, F. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Revisamos los mecanismos de control de crecimiento prostático basados en andrógenos y productos de secreción neuroendocrina, prestando especial atención al papel de la somatostina (SS) como inhibidor del crecimiento neoplásico. Las aportaciones de nuestro grupo confirman que este efecto antiproliferativo de la SS sobre la próstata está mediado por la fosfotirosina fosfatasa SHP-1, presente en la próstata humana. Esta enzima juega un papel en el control de la proliferación celular prostática y en la progresión del cáncer de próstata. Además, pensamos que su presencia podría determinar el potencial terapéutico de la SS en el control del cáncer de próstata (AU)</dc:description>
<dc:source>Actas Urol Esp;28(4): 269-285, abr. 2004. ilus, tab</dc:source>
<dc:identifier>ibc-116713</dc:identifier>
<dc:title xml:lang="es">Fosfotirosina fosfatasa SHP-1, somatostatina y cáncer de próstata</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d22676^s22002</dc:subject>
<dc:subject>^d11914^s22053</dc:subject>
<dc:subject>^d38846</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29866^s22002</dc:subject>
<dc:subject>^d52992^s22053</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>200404</dc:date>
</metadata>
</record>
</ibecs-document>
